Literature DB >> 8726350

Tamoxifen induces TGF-beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro.

H Chen1, T R Tritton, N Kenny, M Absher, J F Chiu.   

Abstract

We report here that the antiestrogen tamoxifen (TAM) induces cell death in human breast cancer cell line MCF-7. We assessed the type of cell death induced by TAM in this breast cancer cell line on the basis of morphological and biochemical characteristics. Dying cells showed morphological characteristics of apoptosis, such as chromatin condensation and nuclear disintegration. DNA isolated from these cells revealed a pattern of distinctive DNA bands on agarose gel. The DNA fragmentation in MCF-7 cells induced by TAM could also be detected by terminal deoxynucleotidyl transferase-mediated dUTP-biotin end labeling. Northern blot hybridization revealed a substantial increase in the amounts of TRPM-2 and TGF-beta 1 mRNAs in MCF-7 cells after treatment with TAM. In contrast, the mRNA level of the estrogen-induced pS2 gene was strongly suppressed. The biological activity of TGF-beta was increased at least fourfold in the media from MCF-7 cells treated with TAM. The results presented in this study suggest that TAM induces apoptosis of MCF-7 cells and it may be mediated by the secretion of active TGF-beta.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726350     DOI: 10.1002/(SICI)1097-4644(19960401)61:1%3C9::AID-JCB2%3E3.0.CO;2-Z

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  24 in total

1.  Estrogen receptors inhibit Smad3 transcriptional activity through Ap-1 transcription factors.

Authors:  Tracy Cherlet; Leigh C Murphy
Journal:  Mol Cell Biochem       Date:  2007-07-28       Impact factor: 3.396

2.  Plasma proteomics analysis of tamoxifen resistance in breast cancer.

Authors:  Keivan Majidzadeh-A; Javad Gharechahi
Journal:  Med Oncol       Date:  2013-10-26       Impact factor: 3.064

3.  Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers.

Authors:  Yong-Hun Lee; William P Schiemann
Journal:  Breast Cancer Manag       Date:  2014

4.  Establishment of a cell-free system of neuronal apoptosis: comparison of premitochondrial, mitochondrial, and postmitochondrial phases.

Authors:  H M Ellerby; S J Martin; L M Ellerby; S S Naiem; S Rabizadeh; G S Salvesen; C A Casiano; N R Cashman; D R Green; D E Bredesen
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

5.  Spatiotemporal dynamics of microRNA during epithelial collective cell migration.

Authors:  Zachary S Dean; Reza Riahi; Pak Kin Wong
Journal:  Biomaterials       Date:  2014-10-23       Impact factor: 12.479

6.  Repurposing ospemifene for potentiating an antigen-specific immune response.

Authors:  Chiao-Jung Kao; Gregory T Wurz; Yi-Chen Lin; Daniel P Vang; Brian Phong; Michael W DeGregorio
Journal:  Menopause       Date:  2017-04       Impact factor: 2.953

7.  Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen.

Authors:  P E Budtz
Journal:  Cell Prolif       Date:  1999-10       Impact factor: 6.831

8.  Analysis of Cre-mediated genetic deletion of Gdf11 in cardiomyocytes of young mice.

Authors:  Jessica Garbern; Amy C Kristl; Vinicius Bassaneze; Ana Vujic; Henk Schoemaker; Rebecca Sereda; Liming Peng; Elisabeth M Ricci-Blair; Jill M Goldstein; Ryan G Walker; Shalender Bhasin; Amy J Wagers; Richard T Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

Review 9.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer.

Authors:  Yongsheng Ren; Liyu Wu; Andra R Frost; William Grizzle; Xu Cao; Mei Wan
Journal:  Mol Cancer       Date:  2009-11-27       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.